galvus News
Most Popular galvus Story
Novartis CEO: Galvus' future is uncertain
Long delayed by a wary FDA, Novartis CEO Daniel Vasella (photo) now says that the diabetes drug Galvus may never be refiled for approval in the U.S. Safety issues arising around liver enzyme levels Read more...
Latest Headlines
- June 9, 2008
- March 26, 2008
- March 20, 2008
- February 1, 2008
- January 17, 2008
- November 6, 2007
- November 2, 2007
- February 28, 2007
- February 25, 2007
- November 12, 2006
- August 16, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
